Shares of Bayer AG (OTCMKTS:BAYRY) have received a consensus rating of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company.
BAYRY has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Bayer from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 13th. Berenberg Bank started coverage on shares of Bayer in a report on Monday, April 1st. They set a “hold” rating on the stock. Deutsche Bank downgraded shares of Bayer from a “buy” rating to a “hold” rating in a report on Sunday, March 31st. Bank of America reaffirmed a “neutral” rating on shares of Bayer in a report on Monday, March 25th. Finally, Bryan, Garnier & Co downgraded shares of Bayer from a “neutral” rating to a “sell” rating in a report on Thursday, March 28th.
BAYRY stock traded down $0.25 during trading on Friday, hitting $15.58. The company had a trading volume of 463,431 shares, compared to its average volume of 704,652. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.59 and a quick ratio of 1.04. Bayer has a 12 month low of $15.45 and a 12 month high of $32.80. The stock has a market capitalization of $58.37 billion, a PE ratio of 8.90, a price-to-earnings-growth ratio of 0.79 and a beta of 0.95.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: What is a recession?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.